Elicio Therapeutics, Inc. Financing Cash Flow
Elicio Therapeutics, Inc. (ELTX) reported Financing Cash Flow of $24.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Elicio Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $16.51M, a 38.37% increase year-over-year.
- Elicio Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $8.03M, a 22.28% decline year-over-year.
- Elicio Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $4.86M, a 2042.29% increase year-over-year.
- Elicio Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $9.57M, a 68.88% decline year-over-year.
- Elicio Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $36.70M, a 13.29% decline from fiscal 2024.
- Elicio Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $42.32M, a 9.60% increase from fiscal 2023.
- Elicio Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $38.61M, a 82.12% increase from fiscal 2022.
- Elicio Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $21.20M, a 80.22% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $16.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $24.54M 10-Q · filed 2026-08-13 | $29.40M derived: sum of 3 quarters · filed 2026-08-13 | $38.97M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $8.03M 10-Q · filed 2026-05-11 | $12.89M derived: sum of 2 quarters · filed 2026-05-11 | $22.46M derived: sum of 3 quarters · filed 2026-05-11 | $34.39M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $4.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $14.44M derived: sum of 2 quarters · filed 2026-03-12 | $26.37M derived: sum of 3 quarters · filed 2026-08-13 | $36.70M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $9.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $21.50M derived: sum of 2 quarters · filed 2026-08-13 | $31.83M 10-Q · filed 2025-11-13 | $32.06M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $11.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $22.26M 10-Q · filed 2026-08-13 | $22.49M derived: sum of 3 quarters · filed 2026-08-13 | $53.24M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $10.33M 10-Q · filed 2026-05-11 | $10.55M derived: sum of 2 quarters · filed 2026-05-11 | $41.31M derived: sum of 3 quarters · filed 2026-05-11 | $41.63M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $30.98M derived: sum of 2 quarters · filed 2026-03-12 | $31.30M derived: sum of 3 quarters · filed 2026-03-12 | $42.32M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $30.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $31.07M derived: sum of 2 quarters · filed 2025-11-13 | $42.09M 10-Q · filed 2025-11-13 | $49.09M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $316.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $11.34M 10-Q · filed 2025-08-07 | $18.34M derived: sum of 3 quarters · filed 2025-08-07 | $18.40M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $11.02M 10-Q · filed 2025-05-13 | $18.02M derived: sum of 2 quarters · filed 2025-05-13 | $18.09M derived: sum of 3 quarters · filed 2025-05-13 | $39.60M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $7.06M derived: sum of 2 quarters · filed 2025-03-31 | $28.57M derived: sum of 3 quarters · filed 2025-03-31 | $38.61M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $21.57M derived: sum of 2 quarters · filed 2024-11-13 | $31.61M 10-Q · filed 2024-11-13 | $31.61M 10-Q · filed 2023-11-13 | $42.79M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $21.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $31.55M 10-Q · filed 2024-08-13 | $42.73M derived: sum of 3 quarters · filed 2024-08-13 | $51.51M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $10.04M 10-Q · filed 2024-05-15 | -$3.27M 10-Q · filed 2023-05-10 | $21.22M derived: sum of 2 quarters · filed 2024-05-15 | $30.00M derived: sum of 3 quarters · filed 2024-05-15 | $31.26M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $11.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $19.95M derived: sum of 2 quarters · filed 2024-03-29 | $21.22M derived: sum of 3 quarters · filed 2024-03-29 | $21.20M 10-K · filed 2024-03-29 | -$60.00K 10-K · filed 2023-03-17 | |||
| 2022-09-30 | $8.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $10.04M derived: sum of 2 quarters · filed 2023-11-13 | $10.03M 10-Q · filed 2023-11-13 | -$45.00K 10-Q · filed 2022-11-14 | $10.43M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.25M 10-Q · filed 2023-08-14 | -$28.00K 10-Q · filed 2022-08-15 | $1.65M derived: sum of 3 quarters · filed 2023-08-14 | $2.35M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | -$14.00K 10-Q · filed 2023-05-10 | $390.00K derived: sum of 2 quarters · filed 2023-05-10 | $1.09M derived: sum of 3 quarters · filed 2023-05-10 | -$1.29M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $1.10M derived: sum of 2 quarters · filed 2023-03-17 | -$1.27M derived: sum of 3 quarters · filed 2023-03-17 | $107.17M 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | $699.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.68M derived: sum of 2 quarters · filed 2022-11-14 | $106.77M 10-Q · filed 2022-11-14 | $106.97M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | -$2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $106.07M 10-Q · filed 2022-08-15 | $106.27M derived: sum of 3 quarters · filed 2022-08-15 | $137.49M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $108.44M 10-Q · filed 2022-05-16 | $108.65M derived: sum of 2 quarters · filed 2022-05-16 | $139.86M derived: sum of 3 quarters · filed 2022-05-16 | $156.92M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $202.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $31.42M derived: sum of 2 quarters · filed 2022-03-30 | $48.47M derived: sum of 3 quarters · filed 2022-03-30 | $52.41M 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | $31.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $48.27M derived: sum of 2 quarters · filed 2021-11-12 | $52.21M 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | $17.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $20.99M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $3.94M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |